W. Timothy Garvey is a Butterworth Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham. He obtained his MD degree from St. Louis University. completed residency training in Internal Medicine at Barnes Hospital. Washington University. and was a clinical fellow in Endocrinology and Metabolism at the University of Colorado Health Sciences Center and University of California. San Diego School of Medicine. He subsequently held faculty posts at UAB. University of California San Diego School of Medicine. Indiana University School of Medicine. and Medical University of South Carolina where he directed the Endocrinology Division.
Dr. Garvey has achieved international recognition for his research in the metabolic. molecular. and genetic pathogenesis of insulin resistance. Type 2 Diabetes. and obesity. His studies have involved the cellular and molecular biology of cell and animal models. metabolic investigations of human subjects on metabolic research wards. and the genetic basis of diseases in Gullah-speaking African Americans. The Garvey laboratory has made important observations regarding the pathogenesis of human insulin resistance and has been a principle contributor to our understanding of the role of the glucose transport system and glucose transporter proteins. He has identified gene families that contribute to insulin resistance in human muscle insulin using cDNA microarray. e.g.. NR4A orphan nuclear receptors and the tribbles gene family. and has elucidated the role of adiponectin in cardiometabolic disease. He has contributed to the training of clinicians. basic scientists. and physician scientists. Since 1987. his laboratory has been supported by the NIH. Department of Veterans Affairs. AHA. JDFI. ADA. and other agencies.
Dr. Garveys career has been distinguished by a second impactful sphere of activity involving our understanding of obesity as a disease. and in advancing medical models to improve the care of patients with obesity. Dr. Garvey was the chief architect of the Complications-Centric Model for Care of the Overweight/Obese Patient. Much of his work in this area has occurred as a board member in the American Association of Clinical Endocrinologists and chair of the AACE Obesity Committee. Dr. Garvey was a lead author in the AACE Position Statement designating Obesity as a disease (Endocrine Practice 18:642. 2012); chair of the AACE Obesity Consensus Conference held in Washington DC in 2014; lead author on the evidence-based AACE obesity management guidelines (Endocr Pract. 22(7):842. 2016); and co-author of the new medical diagnostic term for obesity Adiposity-Based Chronic Disease. This obesity treatment algorithm emphasizes the use of weight loss therapy to treat obesity-related complications as the primary goal of treatment. as opposed to reductions in BMI per se. Further. Dr. Garvey developed Cardiometabolic Disease Staging (Obesity 22:110. 2014) that allows clinicians to quantify risk for Type 2 Diabetes and cardiovascular disease mortality. when deciding upon the intensity of weight loss therapy for their patients. Thus. Dr. Garvey is a national leader in the development of medical models for the management of obesity and diabetes prevention.